CA2437675A1 - Methodes de detection de proteine prion - Google Patents

Methodes de detection de proteine prion Download PDF

Info

Publication number: CA2437675A1
Authority: CA; Canada
Prior art keywords: polypeptide; conformation; epitope; target epitope; agent
Prior art date: 2003-08-20
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002437675A

Other languages

English (en)

Inventor

Neil Cashman

Marty Letho

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Promis Neurosciences Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-08-20

Filing date

2003-08-20

Publication date

2005-02-20

2003-08-20 Application filed by Individual filed Critical Individual

2003-08-20 Priority to CA002437675A priority Critical patent/CA2437675A1/fr

2003-08-21 Priority to CA2437999A priority patent/CA2437999C/fr

2004-08-20 Priority to EP04761667.7A priority patent/EP1668369B1/fr

2004-08-20 Priority to CA2536305A priority patent/CA2536305C/fr

2004-08-20 Priority to US10/568,729 priority patent/US20070003977A1/en

2004-08-20 Priority to AU2004266324A priority patent/AU2004266324B8/en

2004-08-20 Priority to DK04761667.7T priority patent/DK1668369T3/en

2004-08-20 Priority to JP2006523496A priority patent/JP4668191B2/ja

2004-08-20 Priority to PCT/CA2004/001503 priority patent/WO2005019828A1/fr

2004-08-20 Priority to ES04761667.7T priority patent/ES2566565T3/es

2005-02-20 Publication of CA2437675A1 publication Critical patent/CA2437675A1/fr

2006-03-03 Priority to US11/367,609 priority patent/US7439324B2/en

2008-09-24 Priority to US12/236,731 priority patent/US7763710B2/en

2010-06-02 Priority to US12/792,394 priority patent/US8075891B2/en

2010-07-05 Priority to JP2010153006A priority patent/JP5357111B2/ja

2010-10-22 Priority to US12/910,600 priority patent/US9523697B2/en

2011-12-07 Priority to US13/313,869 priority patent/US8828389B2/en

2014-07-31 Priority to US14/448,584 priority patent/US9625476B2/en

2017-03-07 Priority to US15/452,356 priority patent/US20170192020A1/en

Status Abandoned legal-status Critical Current

Links

102000029797 Prion Human genes 0.000 title claims abstract description 39
108091000054 Prion Proteins 0.000 title claims abstract description 39
238000000034 method Methods 0.000 title claims abstract description 38
229920001184 polypeptide Polymers 0.000 claims abstract description 69
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 69
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 69
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 38
239000003795 chemical substances by application Substances 0.000 claims abstract description 34
201000010099 disease Diseases 0.000 claims abstract description 34
102000004169 proteins and genes Human genes 0.000 claims abstract description 31
108090000623 proteins and genes Proteins 0.000 claims abstract description 31
239000003223 protective agent Substances 0.000 claims abstract description 19
102100025818 Major prion protein Human genes 0.000 claims description 72
238000001514 detection method Methods 0.000 claims description 38
CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 claims description 33
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 claims description 14
238000006243 chemical reaction Methods 0.000 claims description 12
238000011282 treatment Methods 0.000 claims description 11
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 claims description 7
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 claims description 7
239000002981 blocking agent Substances 0.000 claims description 6
239000003599 detergent Substances 0.000 claims description 6
208000015181 infectious disease Diseases 0.000 abstract description 18
238000004220 aggregation Methods 0.000 abstract description 14
230000002776 aggregation Effects 0.000 abstract description 13
238000003556 assay Methods 0.000 abstract description 13
238000003745 diagnosis Methods 0.000 abstract description 4
238000004393 prognosis Methods 0.000 abstract description 2
230000001225 therapeutic effect Effects 0.000 abstract description 2
238000004925 denaturation Methods 0.000 abstract 1
230000036425 denaturation Effects 0.000 abstract 1
101710138751 Major prion protein Proteins 0.000 description 70
210000004556 brain Anatomy 0.000 description 47
235000018102 proteins Nutrition 0.000 description 27
239000002253 acid Substances 0.000 description 20
108091005804 Peptidases Proteins 0.000 description 15
239000004365 Protease Substances 0.000 description 15
241000699800 Cricetinae Species 0.000 description 14
239000000523 sample Substances 0.000 description 14
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 13
210000004369 blood Anatomy 0.000 description 13
239000008280 blood Substances 0.000 description 13
239000000126 substance Substances 0.000 description 13
230000004048 modification Effects 0.000 description 12
238000012986 modification Methods 0.000 description 12
210000002700 urine Anatomy 0.000 description 12
238000003119 immunoblot Methods 0.000 description 10
208000008864 scrapie Diseases 0.000 description 10
238000012360 testing method Methods 0.000 description 10
241000283690 Bos taurus Species 0.000 description 9
238000001114 immunoprecipitation Methods 0.000 description 9
102000001708 Protein Isoforms Human genes 0.000 description 8
108010029485 Protein Isoforms Proteins 0.000 description 8
241001465754 Metazoa Species 0.000 description 7
238000002405 diagnostic procedure Methods 0.000 description 7
208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 6
208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 6
208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
235000001014 amino acid Nutrition 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
238000007385 chemical modification Methods 0.000 description 6
150000001875 compounds Chemical class 0.000 description 6
229960004198 guanidine Drugs 0.000 description 6
230000002458 infectious effect Effects 0.000 description 6
230000000903 blocking effect Effects 0.000 description 5
239000010836 blood and blood product Substances 0.000 description 5
230000003247 decreasing effect Effects 0.000 description 5
230000000694 effects Effects 0.000 description 5
238000011534 incubation Methods 0.000 description 5
210000002381 plasma Anatomy 0.000 description 5
JVJFIQYAHPMBBX-UHFFFAOYSA-N 4-hydroxynonenal Chemical compound CCCCCC(O)C=CC=O JVJFIQYAHPMBBX-UHFFFAOYSA-N 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
241000282412 Homo Species 0.000 description 4
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
241001494479 Pecora Species 0.000 description 4
229940125691 blood product Drugs 0.000 description 4
230000029087 digestion Effects 0.000 description 4
239000012530 fluid Substances 0.000 description 4
239000012160 loading buffer Substances 0.000 description 4
238000003118 sandwich ELISA Methods 0.000 description 4
230000035945 sensitivity Effects 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
238000004448 titration Methods 0.000 description 4
241000282994 Cervidae Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
230000002159 abnormal effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
239000013060 biological fluid Substances 0.000 description 3
239000012472 biological sample Substances 0.000 description 3
230000005540 biological transmission Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
230000006378 damage Effects 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
235000013305 food Nutrition 0.000 description 3
239000012678 infectious agent Substances 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
229910052747 lanthanoid Inorganic materials 0.000 description 3
150000002602 lanthanoids Chemical class 0.000 description 3
239000000463 material Substances 0.000 description 3
238000012286 ELISA Assay Methods 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
229920001213 Polysorbate 20 Polymers 0.000 description 2
239000006180 TBST buffer Substances 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000011324 bead Substances 0.000 description 2
239000012148 binding buffer Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
210000005013 brain tissue Anatomy 0.000 description 2
210000001175 cerebrospinal fluid Anatomy 0.000 description 2
208000017580 chronic wasting disease Diseases 0.000 description 2
239000003398 denaturant Substances 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
238000002651 drug therapy Methods 0.000 description 2
239000012634 fragment Substances 0.000 description 2
230000036541 health Effects 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
244000052769 pathogen Species 0.000 description 2
239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 2
235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 2
230000004481 post-translational protein modification Effects 0.000 description 2
238000001556 precipitation Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
230000004845 protein aggregation Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000000758 substrate Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
238000005406 washing Methods 0.000 description 2
238000001262 western blot Methods 0.000 description 2
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 2
AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
102100026882 Alpha-synuclein Human genes 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
101100272788 Arabidopsis thaliana BSL3 gene Proteins 0.000 description 1
101150068401 BSL1 gene Proteins 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
YXHKONLOYHBTNS-UHFFFAOYSA-N Diazomethane Chemical compound C=[N+]=[N-] YXHKONLOYHBTNS-UHFFFAOYSA-N 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
229910052693 Europium Inorganic materials 0.000 description 1
102000020897 Formins Human genes 0.000 description 1
108091022623 Formins Proteins 0.000 description 1
206010018341 Gliosis Diseases 0.000 description 1
101000573901 Homo sapiens Major prion protein Proteins 0.000 description 1
235000019735 Meat-and-bone meal Nutrition 0.000 description 1
241000699673 Mesocricetus auratus Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
101100298534 Mus musculus Prnp gene Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
208000012902 Nervous system disease Diseases 0.000 description 1
208000025966 Neurological disease Diseases 0.000 description 1
101150044568 PRNP gene Proteins 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
102100038836 Superoxide dismutase [Cu-Zn] Human genes 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
239000003463 adsorbent Substances 0.000 description 1
108090000185 alpha-Synuclein Proteins 0.000 description 1
206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
238000004166 bioassay Methods 0.000 description 1
238000010876 biochemical test Methods 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
238000009534 blood test Methods 0.000 description 1
238000009835 boiling Methods 0.000 description 1
208000005881 bovine spongiform encephalopathy Diseases 0.000 description 1
UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
230000006727 cell loss Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
-1 compound peroxynitrite Chemical class 0.000 description 1
230000008876 conformational transition Effects 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
230000005574 cross-species transmission Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
235000015872 dietary supplement Nutrition 0.000 description 1
FFYPMLJYZAEMQB-UHFFFAOYSA-N diethyl pyrocarbonate Chemical compound CCOC(=O)OC(=O)OCC FFYPMLJYZAEMQB-UHFFFAOYSA-N 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
230000005284 excitation Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000007387 gliosis Effects 0.000 description 1
229960000789 guanidine hydrochloride Drugs 0.000 description 1
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
230000000642 iatrogenic effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
238000011813 knockout mouse model Methods 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
238000002595 magnetic resonance imaging Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
239000003607 modifier Substances 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000000626 neurodegenerative effect Effects 0.000 description 1
210000002569 neuron Anatomy 0.000 description 1
230000000802 nitrating effect Effects 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
238000005457 optimization Methods 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
239000008188 pellet Substances 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
238000006303 photolysis reaction Methods 0.000 description 1
230000015843 photosynthesis, light reaction Effects 0.000 description 1
230000001376 precipitating effect Effects 0.000 description 1
239000002243 precursor Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
238000002331 protein detection Methods 0.000 description 1
230000012846 protein folding Effects 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
230000009257 reactivity Effects 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
241000894007 species Species 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000012546 transfer Methods 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
235000002374 tyrosine Nutrition 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
238000012800 visualization Methods 0.000 description 1
238000003260 vortexing Methods 0.000 description 1
239000011534 wash buffer Substances 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Chemical & Material Sciences (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Food Science & Technology (AREA)
General Physics & Mathematics (AREA)
Cell Biology (AREA)
Biotechnology (AREA)
Medicinal Chemistry (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Pathology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Peptides Or Proteins (AREA)

CA002437675A 2003-08-20 2003-08-20 Methodes de detection de proteine prion Abandoned CA2437675A1 (fr)

Priority Applications (18)

Application Number	Priority Date	Filing Date	Title
CA002437675A CA2437675A1 (fr)	2003-08-20	2003-08-20	Methodes de detection de proteine prion
CA2437999A CA2437999C (fr)	2003-08-20	2003-08-21	Methodes de detection d'une proteine prion
PCT/CA2004/001503 WO2005019828A1 (fr)	2003-08-20	2004-08-20	Dosage de protection d'epitope et procede de detection de conformations proteiques
ES04761667.7T ES2566565T3 (es)	2003-08-20	2004-08-20	Ensayo de protección de epítopos y método para detectar conformaciones de proteínas
CA2536305A CA2536305C (fr)	2003-08-20	2004-08-20	Epitopes sod-1 et anticorps
US10/568,729 US20070003977A1 (en)	2003-08-20	2004-08-20	Epitope protection assay and method for detecting protein conformations
AU2004266324A AU2004266324B8 (en)	2003-08-20	2004-08-20	Epitope protection assay and method for detecting protein conformations
DK04761667.7T DK1668369T3 (en)	2003-08-20	2004-08-20	EPITOP PROTECTION ASSAY AND PROCEDURE FOR DETECTION OF PROTEIN COMPLIANCE
JP2006523496A JP4668191B2 (ja)	2003-08-20	2004-08-20	タンパク質立体配座を検出するためのエピトープ保護アッセイおよび方法
EP04761667.7A EP1668369B1 (fr)	2003-08-20	2004-08-20	Dosage de protection d'epitope et procede de detection de conformations proteiques
US11/367,609 US7439324B2 (en)	2003-08-20	2006-03-03	ALS-specific peptide composition
US12/236,731 US7763710B2 (en)	2003-08-20	2008-09-24	ALS-specific peptide composition
US12/792,394 US8075891B2 (en)	2003-08-20	2010-06-02	Antibodies that bind ALS specific epitopes and methods of making
JP2010153006A JP5357111B2 (ja)	2003-08-20	2010-07-05	Ｓｏｄ１ポリペプチド、免疫原、及びミスフォールディングしたｓｏｄ１に対する抗体
US12/910,600 US9523697B2 (en)	2003-08-20	2010-10-22	Detection of pathogenic abeta using an epitope protection assay
US13/313,869 US8828389B2 (en)	2003-08-20	2011-12-07	Methods of diagnosing ALS
US14/448,584 US9625476B2 (en)	2003-08-20	2014-07-31	Methods of diagnosing ALS
US15/452,356 US20170192020A1 (en)	2003-08-20	2017-03-07	Methods of diagnosing als

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CA002437675A CA2437675A1 (fr)	2003-08-20	2003-08-20	Methodes de detection de proteine prion

Publications (1)

Publication Number	Publication Date
CA2437675A1 true CA2437675A1 (fr)	2005-02-20

Family

ID=34230643

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002437675A Abandoned CA2437675A1 (fr)	2003-08-20	2003-08-20	Methodes de detection de proteine prion

Country Status (1)

Country	Link
CA (1)	CA2437675A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005019828A1 (fr)	2003-08-20	2005-03-03	Amorfix Life Sciences Ltd.	Dosage de protection d'epitope et procede de detection de conformations proteiques
US7977314B2 (en)	2005-12-02	2011-07-12	Amorfix Life Sciences Limited	Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
US8513387B2 (en)	2005-12-02	2013-08-20	Amorfix Life Sciences Ltd.	Methods and compositions for detecting amyotrophic lateral sclerosis
US8709422B2 (en)	2005-12-02	2014-04-29	Amorfix Life Sciences Ltd.	Methods and compositions to treat and detect misfolded-SOD1 mediated diseases

2003
- 2003-08-20 CA CA002437675A patent/CA2437675A1/fr not_active Abandoned

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2005019828A1 (fr)	2003-08-20	2005-03-03	Amorfix Life Sciences Ltd.	Dosage de protection d'epitope et procede de detection de conformations proteiques
US8828389B2 (en)	2003-08-20	2014-09-09	Amorfix Life Sciences Ltd.	Methods of diagnosing ALS
US9523697B2 (en)	2003-08-20	2016-12-20	Promis Neurosciences Inc.	Detection of pathogenic abeta using an epitope protection assay
US9625476B2 (en)	2003-08-20	2017-04-18	Promis Neurosciences Inc.	Methods of diagnosing ALS
US7977314B2 (en)	2005-12-02	2011-07-12	Amorfix Life Sciences Limited	Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
US8513387B2 (en)	2005-12-02	2013-08-20	Amorfix Life Sciences Ltd.	Methods and compositions for detecting amyotrophic lateral sclerosis
US8709422B2 (en)	2005-12-02	2014-04-29	Amorfix Life Sciences Ltd.	Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
US8778885B2 (en)	2005-12-02	2014-07-15	Amorfix Life Sciences Ltd.	Methods and compositions to treat and detect misfolded-SOD1 mediated diseases
US9637552B2 (en)	2005-12-02	2017-05-02	Promis Neurosciences Inc.	Methods and compositions to treat and detect misfolded-SOD1 mediated diseases

Legal Events

Date	Code	Title	Description
2008-07-16	EEER	Examination request
2012-01-19	FZDE	Discontinued

Publication	Publication Date	Title
US9523697B2 (en)	2016-12-20	Detection of pathogenic abeta using an epitope protection assay
Soto	2004	Diagnosing prion diseases: needs, challenges and hopes
Turner et al.	2009	An update on the assessment and management of the risk of transmission of variant Creutzfeldt‐Jakob disease by blood and plasma products
CA2693212A1 (fr)	2008-01-31	Methode de detection d'oligomeres beta-amyloides dans des liquides organiques
Sweeney et al.	2000	Molecular analysis of Irish sheep scrapie cases
Kim et al.	2005	Simple and specific detection of abnormal prion protein by a magnetic bead-based immunoassay coupled with laser-induced fluorescence spectrofluorometry
CA2437999C (fr)	2013-10-08	Methodes de detection d'une proteine prion
CA2437675A1 (fr)	2005-02-20	Methodes de detection de proteine prion
CA2536305C (fr)	2015-10-27	Epitopes sod-1 et anticorps
ES2373762T3 (es)	2012-02-08	Ensayo de priones.
Langeveld et al.	2021	Stability of BSE infectivity towards heat treatment even after proteolytic removal of prion protein
JP5322240B2 (ja)	2013-10-23	アレルギー疾患の判定方法及びアレルギー疾患の判定キット
Nunnally et al.	2003	Prions and mad cow disease
Kretzschmar	2003	Diagnosis of prion diseases
CA2518372A1 (fr)	2006-03-30	Peptides pour distinguer des prions
Soto	2005	Detection of prions in blood